(S)-Ondansetron

(S)-Ondansetron

SCHEMBL4543

Cc1nccn1C[C@@H]1CCc2c(c3ccccc3n2C)C1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

HTR3A

The experimentally established mechanism targets of (S)-Ondansetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR3A known ✓ P46098 1/20 1.00
▸ CYP3A4 P08684 2/20 1.00
▸ KCNH2 Q12809 2/20 1.00
▸ CYP1A2 P05177 1/20 1.00
▸ CYP2D6 P10635 1/20 1.00
▸ HTR3E A5X5Y0 1/20 1.00
▸ SLC22A2 O15244 1/20 1.00
▸ SLC22A1 O15245 1/20 1.00
▸ SLC22A3 O75751 1/20 1.00
▸ HTR3B O95264 1/20 1.00
▸ CHRNB2 P17787 1/20 1.00
▸ CHRNB4 P30926 1/20 1.00
▸ CHRNA3 P32297 1/20 1.00
▸ HTR2B P41595 1/20 1.00
▸ CHRNA4 P43681 1/20 1.00
▸ HTR3D Q70Z44 1/20 1.00
▸ SLC47A2 Q86VL8 1/20 1.00
▸ HTR3C Q8WXA8 1/20 1.00
▸ SLC47A1 Q96FL8 1/20 1.00
▸ HDAC1 Q13547 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ondansetron SCHEMBL1560211 1.00 CYP3A4 (1.00) CYP3A4KCNH2CYP1A2CYP2D6HTR3E
Ondansetron SCHEMBL29358872 1.00 CYP3A4 (1.00) CYP3A4KCNH2CYP1A2CYP2D6HTR3E
(R)-Ondansetron SCHEMBL848379 1.00 CYP3A4 (1.00) CYP3A4KCNH2CYP1A2CYP2D6HTR3E
Ondansetron SCHEMBL6059917 1.00 CYP3A4 (1.00) CYP3A4KCNH2CYP1A2CYP2D6HTR3E
(R)-Ondansetron SCHEMBL29742665 1.00 CYP3A4 (1.00) CYP3A4KCNH2CYP1A2CYP2D6HTR3E
Ondansetron SCHEMBL4542 1.00 CYP3A4 (1.00) CYP3A4KCNH2CYP1A2CYP2D6HTR3E
Ondansetron SCHEMBL6186944 0.99 CYP3A4 (0.98) CYP3A4KCNH2CYP1A2CYP2D6HTR3E
Ondansetron SCHEMBL678607 0.99 CYP3A4 (0.98) CYP3A4KCNH2CYP1A2CYP2D6HTR3E
Ondansetron SCHEMBL41455 0.99 CYP3A4 (0.98) CYP3A4KCNH2CYP1A2CYP2D6HTR3E
(R)-Ondansetron SCHEMBL5123895 0.99 CYP3A4 (0.98) CYP3A4KCNH2CYP1A2CYP2D6HTR3E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 42753 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144776-A1 COMBINATION THERAPY FOR A DOPAMINE AGONIST ALTO NEUROSCIENCE, INC. (US) 2026-05-28 — — US claimed
EP-3607938-B1 PHARMACEUTICAL COMPOSITION SOVIC BRKICIC LJILJANA (HR) 2026-05-27 — — EP claimed
CN-122094963-A Cardioprotective lipids and methods of use — 2026-05-26 — — CN claimed
CN-122075410-A Dry powder composition for intranasal delivery — 2026-05-26 — — CN claimed
US-20260130929-A1 USE OF NK1 ANTAGONIST PRODRUG COMPOUND IN COMBINATION WITH 5-HT3 RECEPTOR ANTAGONIST SHANGHAI SHENGDI PHARMACEUTICAL CO LTD (CN) 2026-05-14 — — US claimed
US-12622895-B2 Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases ALTO NEUROSCIENCE, INC. (US) 2026-05-12 — — US claimed
US-12617809-B2 Cardioprotective lipid and method of use SIGNPATH PHARMA, INC. (US) 2026-05-05 — — US claimed
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 — — US claimed
WO-2026090164-A1 COMPOSITIONS COMPRISING ELISMETREP AND A SECOND THERAPEUTIC AGENT FOR TREATING OR PREVENTING MIGRAINE OR PAIN KALLYOPE, INC. (US) 2026-04-30 — — WO claimed
EP-4729123-A2 COMPOSITIONS COMPRISING PRAMIPEXOLE AND A 5HT3 ANTAGONIST FOR USE IN TREATING DEPRESSION Alto Neuroscience, Inc. (US) 2026-04-22 — — EP claimed
EP-0481207-A1 Method for preventing or inhibiting loss of cognitive function employing a combination of an ace inhibitor and a drug that acts at serotonin receptors E.R. SQUIBB & SONS, INC. (US) 1992-04-22 — — EP claimed
EP-0477625-A1 Method for preventing or treating anxiety employing a combination of an ace inhibitor and a drug that acts at serotonin receptors E.R. SQUIBB & SONS, INC. (US) 1992-04-01 — — EP claimed
EP-0477624-A1 Method for preventing or treating depression employing a combination of an ace inhibitor and a drug that acts at serotonin receptors E.R. SQUIBB & SONS, INC. (US) 1992-04-01 — — EP claimed
US-5098889-A Cognition activators, angiotensin converting enzyme inhibitors E. R. SQUIBB & SONS, INC. (US) 1992-03-24 — — US claimed
WO-1992004012-A1 ANTIEMETIC THERAPY ALZA CORPORATION (US) 1992-03-19 — — WO claimed
EP-0467365-A2 Use of a 5-hydroxytryptamine-3(5-HT3) receptor antagonist for the preparation of a pharmaceutical composition for treating urinary incontinence E.R. SQUIBB & SONS, INC. (US) 1992-01-22 — — EP claimed
EP-0450757-A2 Use of 5-hydroxytryptamine-antagonists in the treatment of mental disorders originating in childhood GLAXO GROUP LIMITED (GB) 1991-10-09 — — EP claimed
US-5032578-A Administering inhibitors of angiotensin coverting enzyme to mammals E. R. SQUIBB & SONS, INC. (US) 1991-07-16 — — US claimed
WO-1991009593-A2 5-HT3 ANTAGONISTS FOR TREATMENT OF NAUSEA, BRADYCARDIA OF HYPOTENSION ASSOCIATED WITH MYOCARDIAL INSTABILITY BEECHAM GROUP PLC (GB) 1991-07-11 — — WO claimed
EP-0411900-A2 Medicaments for the treatment of bulimia GLAXO GROUP LIMITED (GB) 1991-02-06 — — EP claimed
Send feedback